Glycoprotein IIb/IIIa Agents in Acute Ischemic Stroke: A Niche in the Making?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41730038.
- Also identified by DOI 10.1161/STROKEAHA.125.053204.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Variations in thrombus composition significantly influence the efficacy of conventional thrombolytic therapies in acute ischemic stroke. Emerging treatments, designed to target distinct components of the thrombus, are currently under evaluation and offer renewed hope for enhancing clot dissolution and improving clinical outcomes. This review will examine the current evidence surrounding glycoprotein IIb/IIIa inhibitors in the treatment of acute ischemic stroke, drawing on the latest randomised-controlled trials, identifying promising therapeutic candidates and evaluating the clinical contexts in which these agents are most likely to be beneficial.
Medical subject headings
- Ischemic Stroke
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Aggregation Inhibitors
- Brain Ischemia